

Application Serial No. 10/726,198

Reply to Office Action mailed September 20, 2007

RECEIVED
CENTRAL FAX CENTER

JUN 20 2008

Amendments to the Claims:

Please enter the following amendments to the claims, with insertions indicated by underlining and deletions by strikethrough.

1. (Previously presented) A composition comprising N-terminally truncated galectin-3, wherein the truncated galectin-3 begins with any of the amino acid residues from Gly-1 through Arg-22 of SEQ ID NO:1 and extends to any of the amino acid residues from Asp-134 through Ile-143 of SEQ ID NO:1 and a pharmaceutically acceptable carrier.
2. (Previously presented) The composition according to claim 1, wherein said N-terminally truncated galectin-3 comprises the amino acid sequence from isoleucine residue 8 through isoleucine residue-143 of SEQ ID NO:1.
3. (Previously presented) The composition according to claim 1, wherein said N-terminally truncated galectin-3 is effective to reduce tumor size in breast cancer.
4. (Previously presented) The composition according to claim 1, wherein said N-terminally truncated Ralectin-3 is effective to reduce metastasis in breast cancer.
- 5-6. (Canceled)
7. (Original) The composition according to claim 1, wherein said composition is formulated for slow release.
8. (Withdrawn, Previously presented) A method of treating a tumor in a patient by administering to a patient in need of treatment a composition according to claim 1.
- 9-10. (Canceled)
11. (Withdrawn, Previously presented) A treatment for cancer comprising administering a composition according to claim 1.

Application Serial No. 10/726,198

Reply to Office Action mailed September 20, 2007

12-13. (canceled)

14. (Withdrawn) The treatment according to claim 11, wherein said N-terminally truncated galectin-3 is present in an amount sufficient to prevent metastasis.

15-20. (Canceled)

21. (Withdrawn, Previously presented) A method of treating a tumor in a patient comprising administering to a patient in need of treatment an effective amount of a nucleic acid sequence encoding an N-terminally truncated galectin-3 wherein the truncated galectin-3 begins with any of the amino acid residues from Gly-1 through Arg-22 of SEQ ID NO:1 and extends to any of the amino acid residues from Asp-134 through Ile-143 of SEQ ID NO:1, in a pharmaceutically acceptable carrier.

22. (Withdrawn, Previously presented) The method according to claim 21, wherein said nucleic acid sequence and carrier are administered intramuscularly, orally, intravenously, or locally.

23-24. (Canceled)

25. (Previously presented) The composition according to claim 1, wherein the N-terminally truncated galectin-3 is derivatized with one or more polyethylene glycol (PEG) molecules.

26. (Previously presented) The composition according to claim 25, wherein the PEG molecules are attached to the N-terminally truncated galectin-3 on Cys-66 of SEQ ID NO:1.

27. (Previously presented) The composition according to claim 1, wherein the N-terminally truncated galectin-3 contains a conserved amino acid substitution at a location selected from the group consisting of Val-95, Val-97, Glu-98, Asp-100, His-101, Phe-102, Val-104, Ala-105, Asp-108, Ala-109, His-110, Tyr-114, His-116, Val-118 and Glu-123 of SEQ ID NO:1.

28. (Previously presented) The composition of claim 1, wherein the N-terminally truncated galectin-3 begins with amino acid residue Ala-2 and extends to amino acid residue Ile-143 of SEQ ID NO:1.

*Application Serial No. 10/726,198
Reply to Office Action mailed September 20, 2007*

29. (Previously presented) The composition of claim 1, wherein the N-terminally truncated galectin-3 begins with amino acid residue Pro-3 and extends to amino acid residue Ile-143 of SEQ ID NO:1.
30. (Previously presented) The composition of claim 1, wherein the N-terminally truncated galectin-3 begins with amino acid residue Ala-4 and extends to amino acid residue Ile-143 of SEQ ID NO:1.
31. (Previously presented) The composition of claim 1, wherein the N-terminally truncated galectin-3 begins with amino acid residue Gly-5 and extends to amino acid residue Ile-143 of SEQ ID NO:1.
32. (Previously presented) The composition of claim 1, wherein the N-terminally truncated galectin-3 begins with amino acid residue Leu-7 and extends to amino acid residue Ile-143 of SEQ ID NO:1.
33. (Previously presented) The composition of claim 1, wherein the N-terminally truncated galectin-3 begins with amino acid residue Val-9 and extends to amino acid residue Ile-143 of SEQ ID NO:1.
34. (Previously presented) The composition of claim 1, wherein the N-terminally truncated galectin-3 begins with amino acid residue Ala-2 and extends to amino acid residue Met-142 of SEQ ID NO:1.
35. (Previously presented) The composition of claim 1, wherein the N-terminally truncated galectin-3 begins with amino acid residues Ala-4 and extends to amino acid residue Thr-142 of SEQ ID NO:1.

Application Serial No. 10/726,198

Reply to Office Action mailed September 20, 2007

36. (Previously presented) The composition of claim 1, wherein the N-terminally truncated galectin-3 begins with amino acid residues Gly-5 and extends to amino acid residue Tyr-141 of SEQ ID NO: 1.

37. (New) The composition according to claim 1, wherein the N-terminally truncated galectin-3 contains a conserved amino acid substitution at Val-95 of SEQ ID NO:1.